TMates Review

What TMates charges

• Semaglutide: $158/mo — from, per month, in the open catalogue
• Tirzepatide: $167/mo — from, per month, in the open catalogue
• NAD+: $88/mo — from, per month, in the open catalogue
• Sermorelin: $129/mo — from, per month, in the open catalogue

Two branded rows that cannot be the drug

The catalogue lists two branded weight-loss injectables at the same low monthly figure, printed exactly like the compounded rows around them.

Those drugs carry published list prices more than ten times higher. The page explains nothing about what its figure covers — whether it is an access fee, a first month, or something else.

Neither is recorded as a price on this record. A figure that cannot plausibly be the drug's price is not filed as the drug's price, and the seller's own trademark attributions at the foot of the page make clear these are the branded products.

An open catalogue for the rest

Semaglutide, tirzepatide, NAD+ and sermorelin each carry a from-price per month on the shop page, alongside products this site does not track.

There is no eligibility gate before the prices, which is less common on this roster than a reader might expect.

Each figure is a floor rather than a rate at a stated dose, so the actual charge depends on what a provider prescribes.

What it says about itself

It says it is not a 503A or 503B compounding facility, which is a specific and checkable claim rather than a vague disclaimer.

It says it may offer compounded medications from registered pharmacies, and that compounded medications are not evaluated by the FDA for safety, quality or efficacy.

It names its operating company in the footer of every page read.

Coverage, stated two ways

The homepage says there is round-the-clock access to doctors in all fifty states.

The shipping question in its own FAQ says it ships to most states.

Neither is a list, and the two do not agree, so no state coverage is credited to this record and no all-fifty claim is credited either.

How we verified this

• Read the shop catalogue row by row and recorded a figure only where the row names a compound this site tracks.
• Declined to record the two branded rows, because the figure is a small fraction of those drugs' published list prices and the page explains nothing about what it buys.
• Recorded every catalogue figure as a floor, in the qualifier, because each is published as a from-price.
• Read both coverage statements and credited neither, because they disagree and neither is a list.
• Screened the brand and the operating company against the live federal warning-letter table, filtering locally because the table's own search parameter returns every record whatever is typed into it, with a positive and a nonsense control in the same run.